{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:57:12Z","timestamp":1792900632994,"version":"4.5.0"},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T00:00:00Z","timestamp":1508976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81621001"],"award-info":[{"award-number":["81621001"]}],"id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Relapse is a common cause of failure in patients with B\u2010cell acute lymphoblastic leukaemia (B\u2010<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>) after haploidentical haematopoietic stem cell transplantation (haplo\u2010<jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content>), and non\u2010responders to donor lymphoblastic infusion after<jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content>have a very poor prognosis. Although donor\u2010derived<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>19\u2010directed chimeric antigen receptor\u2010modified (<jats:styled-content style=\"fixed-case\">CAR<\/jats:styled-content>) T cells can potentially cure leukaemia, their effectiveness and safety have not been confirmed in relapsed B\u2010<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>cases after haplo\u2010<jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content>. Between January 2015 and January 2017, two and four patients each received one and two infusions of<jats:styled-content style=\"fixed-case\">CAR<\/jats:styled-content>T cells from haplo\u2010<jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content>donors. Five (83\u00b733%) achieved minimal residual disease (<jats:styled-content style=\"fixed-case\">MRD<\/jats:styled-content>)\u2010negative remission; one patient was discharged automatically without evaluation after developing severe thrombotic microangiopathies. Four of five responsive patients relapsed after 2\u20137\u00a0months, and one died of sepsis following<jats:styled-content style=\"fixed-case\">MRD<\/jats:styled-content>\u2010negative remission after a second infusion. None of the other second infusion recipients achieved a second complete remission. Five patients (83\u00b733%) experienced eight courses of grade 1\u20133 cytokine release syndrome; two were treated with tocilizumab. Two (33\u00b73%) and one patient developed grade 2 and 3 acute graft\u2010<jats:italic>versus<\/jats:italic>\u2010host disease (<jats:styled-content style=\"fixed-case\">aGVHD<\/jats:styled-content>), respectively; the former was controlled with glucocorticoids. Donor\u2010derived<jats:styled-content style=\"fixed-case\">CAR<\/jats:styled-content>T\u2010cell infusion seems be effective and safe for relapsed B\u2010<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>after haplo\u2010<jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content>, although larger clinical studies are needed.<\/jats:p>","DOI":"10.1111\/bjh.14923","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T02:16:43Z","timestamp":1509070603000},"page":"598-605","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["Donor\u2010derived<scp>CD<\/scp>19\u2010targeted T cell infusion induces minimal residual disease\u2010negative remission in relapsed B\u2010cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation"],"prefix":"10.1111","volume":"179","author":[{"given":"Yuhong","family":"Chen","sequence":"first","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Haematology Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation Collaborative Innovation Centre of Haematology Peking University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Cheng","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Haematology Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation Collaborative Innovation Centre of Haematology Peking University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Suo","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Haematology Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation Collaborative Innovation Centre of Haematology Peking University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhua","family":"Yan","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Haematology Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation Collaborative Innovation Centre of Haematology Peking University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Haematology Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation Collaborative Innovation Centre of Haematology Peking University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Chen","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Haematology Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation Collaborative Innovation Centre of Haematology Peking University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Haematology Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation Collaborative Innovation Centre of Haematology Peking University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanping","family":"Xu","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Haematology Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation Collaborative Innovation Centre of Haematology Peking University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0245-6792","authenticated-orcid":false,"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Haematology Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation Collaborative Innovation Centre of Haematology Peking University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Haematology Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation Collaborative Innovation Centre of Haematology Peking University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lungji","family":"Chang","sequence":"additional","affiliation":[{"name":"Shenzhen Geno\u2010Immune Medical Institute Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xiao","sequence":"additional","affiliation":[{"name":"Innovative Cellular Therapeutics Co. Ltd Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-6643","authenticated-orcid":false,"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Haematology Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation Collaborative Innovation Centre of Haematology Peking University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,10,26]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.5929"},{"key":"e_1_2_8_4_1","first-page":"489","article-title":"[The efficacy and safety of second allogeneic hematopoietic stem cell transplantation for post\u2010transplant hematologic malignancies relapse]","volume":"50","author":"Chen Y.","year":"2011","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"e_1_2_8_5_1","first-page":"421","article-title":"Chimeric antigen receptors T cells as second line therapy for acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation: high remission rate without causing graft versus host disease","volume":"37","author":"Chen Y.","year":"2016","journal-title":"Chinese Journal of Organ Transplantation"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.113860"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1027469"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3845"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.217"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4258"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2941-x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2011.04.002"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705445"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.11.520"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05533.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-519413"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.03.005"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000178"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29146"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2016.1167204"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00500"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.08.023"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27761"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2012.01618.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12168"},{"key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.3760\/cma.j.issn.0366-6999.20141481","article-title":"Immunosuppression for 6\u20138\u00a0weeks after modified donor lymphocyte infusion reduced acute graft\u2010versus\u2010host disease without influencing graft\u2010versus\u2010leukemia effect in haploidentical transplant","volume":"127","author":"Yan C.","year":"2014","journal-title":"Chinese Medical Journal (English)"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.67"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.11.020"},{"key":"e_1_2_8_31_1","first-page":"115","article-title":"Chimeric antigen receptors T cells in treatment of a relapsed pediatric acute lymphoblastic leukemia, relapse after allogenetic hematopoietic stem cell transplantation: case report and review of literature review","volume":"37","author":"Zuo Y.","year":"2016","journal-title":"Zhonghua Xue Ye Xue Za Zhi"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14923","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14923","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T02:21:00Z","timestamp":1719541260000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,26]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1111\/bjh.14923"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14923","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,26]]},"assertion":[{"value":"2017-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}